Transcatheter Valve Replacement for Aortic Stenosis: Balancing Benefits, Risks, and Expectations

Transcatheter Aortic valve replacement (TAVR) represents a transformative technology with potential for the management of complex patients with aortic stenosis, including those who are not considered candidates for surgical aortic valve replacement because of age and medical comorbidities. Currently...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2012-08, Vol.308 (6), p.573-574
Main Authors: Desai, Chintan S, Bonow, Robert O
Format: Article
Language:English
Subjects:
Anticoagulants - administration & dosage
Aortic Valve
Aortic Valve Insufficiency - epidemiology
Aortic Valve Insufficiency - etiology
Aortic Valve Stenosis - therapy
Cardiac Catheterization - adverse effects
Cardiac Catheterization - instrumentation
Cardiac Catheterization - methods
Clinical Trials as Topic
Disease management
Embolism - complications
Embolism - etiology
Europe - epidemiology
Expectations
Heart Block - etiology
Heart Valve Prosthesis Implantation - adverse effects
Heart Valve Prosthesis Implantation - instrumentation
Heart Valve Prosthesis Implantation - methods
Humans
Pacemaker, Artificial
Patient Care Team
Patient Preference
Patient safety
Patient Selection
Registries - statistics & numerical data
Stroke - epidemiology
Stroke - etiology
Surgery
Treatment Outcome
United States - epidemiology
Veins & arteries
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transcatheter Aortic valve replacement (TAVR) represents a transformative technology with potential for the management of complex patients with aortic stenosis, including those who are not considered candidates for surgical aortic valve replacement because of age and medical comorbidities. Currently, more than 50,000 TAVR procedures have been performed worldwide, with mounting enthusiasm for the "rational dispersion" of transcatheter therapies. The US Food and Drug Administration recently approved TAVR as a reasonable alternative to surgical aortic valve replacement in high-risk patients with aortic stenosis. The increasing consumer expectations that this therapy might become available soon for even young, low-risk patients requiring valve replacement must be balanced against safety concerns that have arisen in both clinical trials and registries. Here, Desai and Bonow look at the benefits, risks, and expectations of transcatheter valve replacement for aortic stenosis.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2012.9427